mRNA technology for the prevention and treatment of HIV-1 infection
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · HIV Research and Treatment · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Bekker, L. G. et al. HIV infection. Nat. Rev. Dis. Primers 9, 42 (2023).10.1038/s41572-023-00452-3 ↗
2. Montagnier, L. Historical essay. A history of HIV discovery. Science 298, 1727–1728 (2002).10.1126/science.1079027 ↗
3. Chen, L. et al. Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat. Commun. 9, 4585 (2018).10.1038/s41467-018-07006-2 ↗
4. Landovitz, R. J., Scott, H. & Deeks, S. G. Prevention, treatment and cure of HIV infection. Nat. Rev. Microbiol. 21, 657–670 (2023).10.1038/s41579-023-00914-1 ↗
5. Gbadamosi, S. O., Trepka, M. J., Dawit, R., Jebai, R. & Sheehan, D. M. A systematic review and meta-analysis to estimate the time from HIV infection to diagnosis for people with HIV. AIDS Rev. 24, 32–40 (2022).
6. Bartlett, J. A. & Shao, J. F. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect. Dis. 9, 637–649 (2009).10.1016/S1473-3099(09)70227-0 ↗
7. Grinsztejn, B. et al. Third-line antiretroviral therapy in low-income and middle-income countries: ACTG A5288, a prospective strategy study. Lancet HIV 6, e588–e600 (2019).10.1016/S2352-3018(19)30146-8 ↗
8. Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142–158 (2023).10.1038/s41577-022-00753-w ↗
9. Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179–1188 (2018).10.1038/s41590-018-0235-7 ↗
10. Goo, L., Chohan, V., Nduati, R. & Overbaugh, J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat. Med. 20, 655–658 (2014).10.1038/nm.3565 ↗
11. Escolano, A. et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 166, 1445–1458.e12 (2016).10.1016/j.cell.2016.07.030 ↗
12. Steichen, J. M. et al. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates. Science 384, eadj8321 (2024).10.1126/science.adj8321 ↗
13. Willis, J. R. et al. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science 389, eadr8382 (2025).10.1126/science.adr8382 ↗
14. Kelsoe, G. & Haynes, B. F. Host controls of HIV broadly neutralizing antibody development. Immunol. Rev. 275, 79–88 (2017).10.1111/imr.12508 ↗
15. Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).10.1038/ni.3158 ↗
16. Kwong, P. D., Mascola, J. R. & Nabel, G. J. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13, 693–701 (2013).10.1038/nri3516 ↗
17. Barouch, D. H. et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392, 232–243 (2018).10.1016/S0140-6736(18)31364-3 ↗
18. Barouch, D. H. et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349, 320–324 (2015).10.1126/science.aab3886 ↗
19. Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089–1100 (2021).10.1056/NEJMoa2031499 ↗
20. Gray, G. E. et al. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Infect. Dis. 24, 1201–1212 (2024).10.1016/S1473-3099(24)00358-X ↗
21. Kay, M. A. AAV vectors and tumorigenicity. Nat. Biotechnol. 25, 1111–1113 (2007).10.1038/nbt1007-1111 ↗
22. Donsante, A. et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477 (2007).10.1126/science.1142658 ↗
23. Nguyen, G. N. et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat. Biotechnol. 39, 47–55 (2021).10.1038/s41587-020-0741-7 ↗
24. Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 136–150 (2020).10.1016/j.cell.2020.03.023 ↗
25. Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines — a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).10.1038/nrd.2017.243 ↗
26. Mu, Z., Haynes, B. F. & Cain, D. W. HIV mRNA vaccines — progress and future paths. Vaccines 9, 134 (2021).10.3390/vaccines9020134 ↗
27. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
28. Chaudhary, N., Weissman, D., Whitehead, K. A., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817–838 (2021).10.1038/s41573-021-00283-5 ↗
29. McGee, J. E. et al. Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency. Nat. Biotechnol. 43, 720–726 (2025).10.1038/s41587-024-02306-z ↗
30. Wu, X. et al. The impact of COVID-19 non-pharmaceutical interventions on HIV care continuum in China: an interrupted time series analysis. Lancet Reg. Health West. Pac. 29, 100569 (2022).
31. Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215, 1571–1588 (2018).10.1084/jem.20171450 ↗
32. Huang, X. et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 17, 1027–1037 (2022).10.1038/s41565-022-01174-5 ↗
33. Meulewaeter, S. et al. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J. Control. Rel. 357, 149–160 (2023).10.1016/j.jconrel.2023.03.039 ↗
34. Ju, Y. et al. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines. Nat. Rev. Immunol. 23, 135–136 (2023).10.1038/s41577-022-00825-x ↗
35. Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).10.1126/science.abm0829 ↗
36. Riddler, S. A. et al. High frequency of chronic urticaria following an investigational HIV-1 BG505 MD39.3 trimer mRNA vaccine in a phase 1, randomized, open-label clinical trial (HVTN 302). Ann. Intern. Med. 178, 963–974 (2025).10.7326/ANNALS-24-02701 ↗
37. Parks, K. R. et al. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci. Transl. Med. 17, eady6831 (2025).10.1126/scitranslmed.ady6831 ↗
38. Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).10.1038/ncomms14630 ↗
39. Zhang, P. et al. A multiclade env–gagVLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat. Med. 27, 2234–2245 (2021).10.1038/s41591-021-01574-5 ↗
40. Engelman, A. & Cherepanov, P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat. Rev. Microbiol. 10, 279–290 (2012).10.1038/nrmicro2747 ↗
41. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884–1888 (1998).10.1126/science.280.5371.1884 ↗
42. Julien, J.-P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477–1483 (2013).10.1126/science.1245625 ↗
43. Stano, A. et al. Dense array of spikes on HIV-1 virion particles. J. Virol. 91, https://doi.org/10.1128/jvi.00415-17 (2017).10.1128/jvi.00415-17 ↗
44. Mansky, L. M. The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222, 391–400 (1996).10.1006/viro.1996.0436 ↗
45. Leitner, T. & Albert, J. The molecular clock of HIV-1 unveiled through analysis of a known transmission history. Proc. Natl Acad. Sci. USA 96, 10752–10757 (1999).10.1073/pnas.96.19.10752 ↗
46. Hemelaar, J. The origin and diversity of the HIV-1 pandemic. Trends Mol. Med. 18, 182–192 (2012).10.1016/j.molmed.2011.12.001 ↗
47. McLaren, P. J. & Carrington, M. The impact of host genetic variation on infection with HIV-1. Nat. Immunol. 16, 577–583 (2015).10.1038/ni.3147 ↗
48. Simon, V., Bloch, N. & Landau, N. R. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol. 16, 546–553 (2015).10.1038/ni.3156 ↗
49. Burton, D. R. & Hangartner, L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34, 635–659 (2016).10.1146/annurev-immunol-041015-055515 ↗
50. Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl. Med. 11, eaaz2686 (2019).10.1126/scitranslmed.aaz2686 ↗
51. Liu, M. et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J. Virol. 89, 784–798 (2015).10.1128/JVI.02378-14 ↗
52. Yang, G. et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 210, 241–256 (2013).10.1084/jem.20121977 ↗
53. Steichen, J. M. et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 45, 483–496 (2016).10.1016/j.immuni.2016.08.016 ↗
54. Jardine, J. G. et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351, 1458–1463 (2016).10.1126/science.aad9195 ↗
55. Huang, D. et al. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proc. Natl Acad. Sci. USA 117, 22920–22931 (2020).10.1073/pnas.2004489117 ↗
56. Bruel, T. et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun. 7, 10844 (2016).10.1038/ncomms10844 ↗
57. Liu, Y., Cao, W., Sun, M. & Li, T. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg. Microbes Infect. 9, 194–206 (2020).10.1080/22221751.2020.1713707 ↗
58. Chun, T.-W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188 (1997).10.1038/387183a0 ↗
59. Maldarelli, F. et al. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).10.1126/science.1254194 ↗
60. Douek, D. C. et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417, 95–98 (2002).10.1038/417095a ↗
61. Goulder, P. J. R. & Watkins, D. I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8, 619–630 (2008).10.1038/nri2357 ↗
62. Desrosiers, R. C. Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat. Med. 5, 723–725 (1999).10.1038/10439 ↗
63. Walker, B. D. & Yu, X. G. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 13, 487–498 (2013).10.1038/nri3478 ↗
64. Bailon, L. et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial. Nat. Med. 28, 2611–2621 (2022).10.1038/s41591-022-02060-2 ↗
65. Gaiha, G. D. et al. Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science 364, 480–484 (2019).10.1126/science.aav5095 ↗
66. Kopycinski, J. et al. Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions. Sci. Rep. 13, 17155 (2023).10.1038/s41598-023-42888-3 ↗
67. Lee, J. H. et al. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature 609, 998–1004 (2022).10.1038/s41586-022-05216-9 ↗
68. Wang, X. et al. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models. Sci. Immunol. 9, eadn0622 (2024).10.1126/sciimmunol.adn0622 ↗
69. Xie, Z. et al. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science 384, eadk0582 (2024).10.1126/science.adk0582 ↗
70. Wood, J. M. & Robertson, J. S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2, 842–847 (2004).10.1038/nrmicro979 ↗
71. Lauring, A. S., Jones, J. O. & Andino, R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28, 573–579 (2010).10.1038/nbt.1635 ↗
72. McMichael, A. J. & Hanke, T. HIV vaccines 1983–2003. Nat. Med. 9, 874–880 (2003).10.1038/nm0703-874 ↗
73. Burton, D. R. Advancing an HIV vaccine; advancing vaccinology. Nat. Rev. Immunol. 19, 77–78 (2019).10.1038/s41577-018-0103-6 ↗
74. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).10.1056/NEJMoa1113425 ↗
75. Hammer, S. M. et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083–2092 (2013).10.1056/NEJMoa1310566 ↗
76. Gebre, M. S. et al. Novel approaches for vaccine development. Cell 184, 1589–1603 (2021).10.1016/j.cell.2021.02.030 ↗
77. Travieso, T., Li, J., Mahesh, S., Mello, J. & Blasi, M. The use of viral vectors in vaccine development. npj Vaccines 7, 75 (2022).10.1038/s41541-022-00503-y ↗
78. Picker, L. J., Lifson, J. D., Gale, M. Jr, Hansen, S. G. & Fruh, K. Programming cytomegalovirus as an HIV vaccine. Trends Immunol. 44, 287–304 (2023).10.1016/j.it.2023.02.001 ↗
79. Verweij, M. C. et al. Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy. Science 372, eabe9233 (2021).10.1126/science.abe9233 ↗
80. Borducchi, E. N. et al. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284–287 (2016).10.1038/nature20583 ↗
81. Barouch, D. H. & Deeks, S. G. Immunologic strategies for HIV-1 remission and eradication. Science 345, 169–174 (2014).10.1126/science.1255512 ↗
82. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).10.1056/NEJMoa0908492 ↗
83. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008).10.1016/S0140-6736(08)61591-3 ↗
84. McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. & Haynes, B. F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10, 11–23 (2010).10.1038/nri2674 ↗
85. Barouch, D. H. Challenges in the development of an HIV-1 vaccine. Nature 455, 613–619 (2008).10.1038/nature07352 ↗
86. Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C. & Ravetch, J. V. Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165, 1609–1620 (2016).10.1016/j.cell.2016.04.050 ↗
87. Saunders, K. O. et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J. Virol. 89, 5895–5903 (2015).10.1128/JVI.00210-15 ↗
88. Pegu, A. et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6, 243ra288 (2014).10.1126/scitranslmed.3008992 ↗
89. Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061–2074 (2014).10.1084/jem.20132494 ↗
90. Martinez-Navio, J. M. et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567–575.e5 (2019).10.1016/j.immuni.2019.02.005 ↗
91. Gardner, M. R. Promise and progress of an HIV-1 cure by adeno-associated virus vector delivery of anti-HIV-1 biologics. Front. Cell Infect. Microbiol. 10, 176 (2020).10.3389/fcimb.2020.00176 ↗
92. Priddy, F. H. et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6, e230–e239 (2019).10.1016/S2352-3018(19)30003-7 ↗
93. Casazza, J. P. et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat. Med. 28, 1022–1030 (2022).10.1038/s41591-022-01762-x ↗
94. Nahmad, A. D. et al. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat. Biotechnol. 40, 1241–1249 (2022).10.1038/s41587-022-01328-9 ↗
95. Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat. Mater. 20, 701–710 (2021).10.1038/s41563-020-00886-0 ↗
96. Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).10.1038/s41467-020-14527-2 ↗
97. Langer, R. & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797–800 (1976).10.1038/263797a0 ↗
98. Dimitriadis, G. J. Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 274, 923–924 (1978).10.1038/274923a0 ↗
99. Ostro, M. J., Giacomoni, D., Lavelle, D., Paxton, W. & Dray, S. Evidence for translation of rabbit globin mRNA after liposome-mediated insertion into a human cell line. Nature 274, 921–923 (1978).10.1038/274921a0 ↗
100. Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).10.1038/nature21428 ↗